Latest pharma news update... Oct 29
... Jul 17
... Jun 25
Recommendation based on positive results from the Phase 3 CheckMate -577 trial in which Opdivo doubled disease-free survival compared to placebo in the all-... Jun 25
The companies are planning to move into the registrational stage of development for this asset as early as next year.... Jun 21
... Jun 18
Significantly improves progression-free Survival vs. Opdivo (nivolumab) in patients... May 22
The antibody is indicated for patients with previously untreated Metastatic or unresectable melanoma... Mar 27
Compugen Ltd expands collaboration agreement with Bristol Myers Squibb with phase 1b combination study of COM701 with opdivo C... Feb 22
Molecular Templates collaborates with Bristol Myers Squibb for the discovery and development of next generation engineered toxin bodies ... Feb 17
The pharma stocks for long term wealth creation ... Jan 11
... Jan 05
If approved, Zeposia would be the first oral sphingosine-1-phosphate (S1P) receptor modulator for the treatment of ulcerative colitis.... Dec 28
... Dec 23
Cipla wins the litigation case against Bristol Myers Squibb... Dec 12
If approved, Inrebic will become the first new therapy for myelofibrosis in Europe in nearly a decade.... Dec 11
Results demonstrated treatment with Onureg improved overall survival, compared to placebo, in patients with AML in first remission.... Dec 08
Bristol Myers Squibb announced the approval of Opdivo for the treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma ... Nov 25
The Bristol Myers Squibb–Pfizer Alliance, with the support of leading advocacy organizations and medical societies, announces the launch of the No Time to Wait ... Oct 26
Results from CheckMate -9ER recently presented during a Presidential Symposium at the European Society for Medical Oncology Virtual Congress... Oct 19
The acquisition of MyoKardia further strengthens Bristol Myers Squibb's portfolio, pipeline and scientific capabilities... Oct 12
Opdivo + Yervoy is the first new systemic therapy in over 15 years to be approved by the FDA ... Oct 03
Latest Pharma acquisation news Sep 23, 2020... Sep 23
Bristol Myers Squibb provides update on phase 3 IDHENTIFY trial in patients with relapsed or refractory acute myeloid leukemia ... Aug 27
Forbius’s lead TGF-beta asset, AVID200, is an isoform-selective TGF-beta inhibitor, currently in phase 1 for oncology and fibrosis ... Aug 26
-Advertisements-
.jpeg)
Thursday, October 08, 2026
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)